Day: January 14, 2024

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and providers to resolve system-wide challenges hindering positive patient pathways from primary settings through to recovery. The Economist Impact – Musculoskeletal Injuries in Australia Report outlines the growing number of meniscal injury (MI) and rotator cuff (RC) injuries in Australia. It seeks to find solutions to ensure patients in Australia access better care for acute soft tissue injuries, and that a multi-party solution is adopted to address risks and gaps in current practices care looking at diagnostic techniques, referral mechanisms, and cost considerations of different reimbursement and/or compensation schemes.Smith+Nephew...

Preliminary results of the mandatory offer to acquire all shares in BW Energy Limited Reference is made to the mandatory offer by BW Group Limited (the “Offeror”) to acquire all outstanding shares (“Shares”) in BW Energy Limited (“BW Energy” or the “Company”) not already owned by the Offeror at an offer price of NOK 27.00 per share pursuant to the offer document (the “Offer Document”) dated 13 December 2023 (the “Offer”).  This action was taken in accordance with the Norwegian Securities Trading Act which obliges a shareholder becoming owner of shares representing 40% or more of the votes in the company to make an offer to purchase the remaining shares in the company. The offer period in the Offer (the “Offer Period”) expired at 16:30 (CET) on 12 January...

DISCLOSURE OF SHAREHOLDING Reference is made to the mandatory offer by BW Group Limited (the “Offeror” or “BW Group”) to acquire all outstanding shares (“Shares”) in BW Energy Limited (“BW Energy” or the “Company”) not already owned by the Offeror at an offer price of NOK 27.00 per share pursuant to the offer document (the “Offer Document”) dated 13 December 2023 (the “Offer”), and the announcement of the preliminary results of the Offer published earlier today, 14 January 2024. During 12 January 2024, being the last day of the offer period in the Offer, BW Group received acceptances for 30,493,614 Shares. In total, BW Group received acceptances of the Offer for 30,861,366 Shares. Following this BW Group holds 134,063,836 Shares in BW Energy, representing...

Singh’s appointment comes in support of the Company’s next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently developed health-related concerns. McAuley will assume an advisory role to Mr. Singh during the transition to continue facilitating the company’s...

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicle ZORYVE foam provided rapid and significant improvement in quality of life scores in patients 17 years and older Data presented at the 2024 Winter Clinical Dermatology Conference – HawaiiWESTLAKE VILLAGE, Calif., Jan. 14, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times...

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved measurable improvement by Week 1 (the earliest timepoint measured) Data presented at the 2024 Winter Clinical Dermatology Conference – HawaiiWESTLAKE VILLAGE, Calif., Jan. 14, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new individual patient response data showing the vast majority of individuals (91.5%) treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks. New pooled analyses from two pivotal Phase...